UOC
TEVA icon

UBS O'Connor’s Teva Pharmaceuticals TEVA Stock Holding History

UBS O'Connor’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-223,596
Closed -$3.75M – 438
2025
Q2 		$3.75M Buy
223,596
+122,808
+122% +$1.98M 0.1% 94
2025
Q1 		$1.55M Sell
100,788
-37,237
-27% -$665K 0.04% 146
2024
Q4 		$3.04M Buy
138,025
+58,893
+74% +$1.07M 0.08% 121
2024
Q3 		$1.43M Buy
79,132
+28,236
+55% +$494K 0.04% 232
2024
Q2 		$827K Buy
50,896
+6,000
+13% +$92.4K 0.02% 321
2024
Q1 		$633K Sell
44,896
-45,121
-50% -$569K 0.02% 317
2023
Q4 		$940K Sell
90,017
-94,983
-51% -$887K 0.03% 277
2023
Q3 		$1.89M Buy
+185,000
New +$1.72M 0.03% 254
2018
Q3 		– Sell
-22,000
Closed -$535K – 328
2018
Q2 		$535K Buy
+22,000
New +$449K 0.01% 232
2017
Q4 		– Sell
-40,000
Closed -$704K – 376
2017
Q3 		$704K Buy
+40,000
New +$900K 0.01% 299

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

UBS O'Connor's TEVA Position: Q3 2025 in Review

UBS O'Connor sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 223,596 shares — an estimated $3.75M sold.

UBS O'Connor first reported a position in TEVA in Q3 2017 and held it in 10 quarters. The position peaked at $3.75M in Q2 2025. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • UBS O'Connor reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 223,596 Teva Pharmaceuticals shares in Q3 2025, an estimated $3.75M.
  • UBS O'Connor first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 10 quarters.
  • UBS O'Connor's Teva Pharmaceuticals position peaked at $3.75M in Q2 2025.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.